Report Detail
Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Insights, Forecast to 2025
- RnM3061418 |
- 05 March, 2019 |
- Global |
- 129 Pages |
- QYResearch |
- Pharma & Healthcare
The global Proprotein Convertase Subtilisin/Kexin Type 9 market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Proprotein Convertase Subtilisin/Kexin Type 9 market based on company, product type, end user and key regions.
This report studies the global market size of Proprotein Convertase Subtilisin/Kexin Type 9 in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Proprotein Convertase Subtilisin/Kexin Type 9 in these regions.
This research report categorizes the global Proprotein Convertase Subtilisin/Kexin Type 9 market by top players/brands, region, type and end user. This report also studies the global Proprotein Convertase Subtilisin/Kexin Type 9 market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Market size by Product
SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others
Market size by End User
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Proprotein Convertase Subtilisin/Kexin Type 9 market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Proprotein Convertase Subtilisin/Kexin Type 9 market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Proprotein Convertase Subtilisin/Kexin Type 9 companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Proprotein Convertase Subtilisin/Kexin Type 9 submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Proprotein Convertase Subtilisin/Kexin Type 9 are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Proprotein Convertase Subtilisin/Kexin Type 9 market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Proprotein Convertase Subtilisin/Kexin Type 9 Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth Rate by Product
- 1.4.2 SX-PCK9
- 1.4.3 O-304
- 1.4.4 K-312
- 1.4.5 BLSM-201
- 1.4.6 DCRPCSK-9
- 1.4.7 Others
- 1.5 Market by End User
- 1.5.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth Rate by End User
- 1.5.2 Cardiovascular Disease
- 1.5.3 Homozugous Familial Hyperchalesterolemia
- 1.5.4 Liver Disease
- 1.5.5 Metabolic Syndrome
- 1.5.6 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size
- 2.1.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue 2014-2025
- 2.1.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales 2014-2025
- 2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Growth Rate by Regions
- 2.2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Regions
- 2.2.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Manufacturers
- 3.1.1 Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Manufacturers
- 3.1.2 Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Manufacturers
- 3.1.3 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Concentration Ratio (CR5 and HHI)
- 3.2 Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Manufacturers
- 3.2.1 Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Manufacturers (2014-2019)
- 3.2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Share by Manufacturers (2014-2019)
- 3.3 Proprotein Convertase Subtilisin/Kexin Type 9 Price by Manufacturers
- 3.4 Proprotein Convertase Subtilisin/Kexin Type 9 Manufacturing Base Distribution, Product Types
- 3.4.1 Proprotein Convertase Subtilisin/Kexin Type 9 Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Proprotein Convertase Subtilisin/Kexin Type 9 Product Type
- 3.4.3 Date of International Manufacturers Enter into Proprotein Convertase Subtilisin/Kexin Type 9 Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Product
- 4.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Product
- 4.3 Proprotein Convertase Subtilisin/Kexin Type 9 Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by End User
6 North America
- 6.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 by Countries
- 6.1.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Countries
- 6.1.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 by Product
- 6.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 by End User
7 Europe
- 7.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 by Countries
- 7.1.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Countries
- 7.1.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 by Product
- 7.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 by End User
8 Asia Pacific
- 8.1 Asia Pacific Proprotein Convertase Subtilisin/Kexin Type 9 by Countries
- 8.1.1 Asia Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Countries
- 8.1.2 Asia Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Proprotein Convertase Subtilisin/Kexin Type 9 by Product
- 8.3 Asia Pacific Proprotein Convertase Subtilisin/Kexin Type 9 by End User
9 Central & South America
- 9.1 Central & South America Proprotein Convertase Subtilisin/Kexin Type 9 by Countries
- 9.1.1 Central & South America Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Countries
- 9.1.2 Central & South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Proprotein Convertase Subtilisin/Kexin Type 9 by Product
- 9.3 Central & South America Proprotein Convertase Subtilisin/Kexin Type 9 by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 by Countries
- 10.1.1 Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Sales by Countries
- 10.1.2 Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 by Product
- 10.3 Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 by End User
11 Company Profiles
- 11.1 AFFiRiS AG
- 11.1.1 AFFiRiS AG Company Details
- 11.1.2 Company Business Overview
- 11.1.3 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.1.5 AFFiRiS AG Recent Development
- 11.2 Betagenon AB
- 11.2.1 Betagenon AB Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.2.5 Betagenon AB Recent Development
- 11.3 Bioleaders Corp
- 11.3.1 Bioleaders Corp Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.3.5 Bioleaders Corp Recent Development
- 11.4 BioLingus AG
- 11.4.1 BioLingus AG Company Details
- 11.4.2 Company Business Overview
- 11.4.3 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.4.5 BioLingus AG Recent Development
- 11.5 Catabasis Pharmaceuticals Inc
- 11.5.1 Catabasis Pharmaceuticals Inc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.5.5 Catabasis Pharmaceuticals Inc Recent Development
- 11.6 Dicerna Pharmaceuticals Inc
- 11.6.1 Dicerna Pharmaceuticals Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.6.5 Dicerna Pharmaceuticals Inc Recent Development
- 11.7 Eli Lilly and Co
- 11.7.1 Eli Lilly and Co Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.7.5 Eli Lilly and Co Recent Development
- 11.8 Ensemble Therapeutics Corp
- 11.8.1 Ensemble Therapeutics Corp Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.8.5 Ensemble Therapeutics Corp Recent Development
- 11.9 Kowa Co Ltd
- 11.9.1 Kowa Co Ltd Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.9.5 Kowa Co Ltd Recent Development
- 11.10 Novartis AG
- 11.10.1 Novartis AG Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Products Offered
- 11.10.5 Novartis AG Recent Development
- 11.11 Pfizer Inc
- 11.12 Regeneron Pharmaceuticals Inc
- 11.13 Serometrix LLC
- 11.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- 11.15 The Medicines Company
12 Future Forecast
- 12.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market Forecast by Regions
- 12.1.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales Forecast by Regions 2019-2025
- 12.1.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Forecast by Regions 2019-2025
- 12.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Forecast by Product
- 12.2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Sales Forecast by Product 2019-2025
- 12.2.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Forecast by Product 2019-2025
- 12.3 Proprotein Convertase Subtilisin/Kexin Type 9 Market Forecast by End User
- 12.4 North America Proprotein Convertase Subtilisin/Kexin Type 9 Forecast
- 12.5 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Forecast
- 12.6 Asia Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Forecast
- 12.7 Central & South America Proprotein Convertase Subtilisin/Kexin Type 9 Forecast
- 12.8 Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Proprotein Convertase Subtilisin/Kexin Type 9 Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Proprotein Convertase Subtilisin/Kexin Type 9 . Industry analysis & Market Report on Proprotein Convertase Subtilisin/Kexin Type 9 is a syndicated market report, published as Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
